Application of heart-nourishing Damwaemery honey cream in preparation of myocardial infarction rehabilitation product
By using Yangxin Dawayimisik Honey Cream as the main ingredient of myocardial infarction rehabilitation products, the side effects and high cost of the existing technology center myocardial infarction treatment have been solved, significantly improving the heart function after myocardial infarction and reducing inflammation and fiber , providing a safe and effective treatment strategy.
Patent Information
- Application Number
- CN202411051278.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art methods for treating myocardial infarction have great side effects and high cost, and lack safe and effective treatment strategies.
Yangxin Dawayimisik honey cream is used as the main ingredient in the preparation of myocardial infarction rehabilitation products. It is used to inhibit the expression of related genes and proteins and improve the heart function after myocardial infarction. , reduces inflammatory infiltration and fibrosis.
It significantly improves the heart function after myocardial infarction, prevents heart failure, reduces the expression of apoptotic genes and proteins, inhibits the process of heart fibrosis, and has better effects than traditional drugs.
Smart Images

Figure CN118975975A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to application of a heart-nourishing Dawa Yimixike honey paste in preparing a myocardial infarction rehabilitation product. Background Art
[0002] Acute myocardial infarction (AMI) refers to a disease in which blood supply is sharply reduced or completely interrupted on the basis of severe coronary artery lesions, resulting in severe and persistent acute ischemia, myocardial cell necrosis and local myocardial infarction. It is also the most serious manifestation of coronary artery disease. Myocardial infarction (MI) causes myocardial cell damage, myocardial fibroblasts are activated and differentiated into myofibroblasts, and eventually causes the formation of fibrotic scars in the heart. Due to changes in ventricular morphology and structure, hemodynamics changes accordingly, leading to heart failure [Reference: hen W, Bian W, Zhou Y, et al. Cardiac Fibroblasts and Myocardial Regeneration [J]. Front Bioeng Biotechnol, 2021, 9: 599928.]. The treatment principle of myocardial infarction is to restore myocardial blood perfusion as soon as possible, protect and maintain cardiac function, save dying myocardium, and prevent the expansion of infarction area. Myocardial infarction has a fast incidence rate and a very high mortality rate. Even if it is treated in time, the recurrence rate is usually very high. At present, interventional therapy is the first choice for the treatment of myocardial infarction, which removes blood clots through surgery to make blood flow smoothly, but the surgery is expensive and has serious side effects; secondly, drug thrombolysis can also restore blood vessel patency by 50%-70%, but taking a large amount of drugs will also bring a series of side effects. Therefore, there is an urgent need for safe and effective new treatment strategies to improve the symptoms of myocardial infarction, inhibit the progression of the disease, and relieve patients' pain.
[0003] Yangxin Dawa Yimixike honey paste has many functions, such as calming the mind, promoting blood circulation and removing blood stasis, nourishing the brain and strengthening the heart, strengthening the stomach and refreshing the mind, etc. It is diagnosed in traditional Chinese medicine for the treatment of nourishing the mind and calming the mind, calming and relieving restlessness, promoting qi and promoting blood circulation, and dredge meridians and relieve pain; it is diagnosed in Western medicine for the treatment of coronary atherosclerotic heart disease, angina pectoris, arrhythmia, and insomnia. At present, clinical studies have confirmed that Yangxin Dawa Yimixike honey paste has significant therapeutic effects on cardiovascular diseases such as coronary heart disease, arrhythmia, and angina pectoris. However, the relevant research on the treatment of myocardial infarction with Yangxin Dawa Yimixike honey paste is still limited. Summary of the invention
[0004] The technical problem to be solved by the present invention is to solve the problem that the existing methods for treating myocardial infarction have large side effects and high costs, and provide an application of Yangxin Dawa Yimixike Honey Paste in the preparation of myocardial infarction rehabilitation products. By evaluating the Yangxin Dawa Yimixike Honey Paste in the rehabilitation treatment of myocardial infarction, it was found that Yangxin Dawa Yimixike Honey Paste has a significant protective effect on the heart of myocardial infarction model rats, can significantly improve cardiac function after myocardial infarction, reduce inflammatory infiltration, reduce the expression of apoptosis genes and proteins, and effectively inhibit the occurrence of cardiac fibrosis.
[0005] The present invention provides an application of Yangxin Dawa Yimixike honey paste in preparing a myocardial infarction rehabilitation product, wherein the myocardial infarction is type 1 myocardial infarction.
[0006] The present invention also provides an application of Yangxin Dawa Yimixike honey paste in preparing the following ① or ② products: ① IL-1β expression inhibitor, ② NT-proBNP expression inhibitor.
[0007] The present invention also provides an application of Yangxin Dawa Yimixike Honey Paste in preparing any one of the following products ① to ③: ① VDAC1 expression inhibitor, ② 3 NLRP3 expression inhibitor, ③ Bax / BCL-2 inhibitor, Bax / BCL-2 refers to the ratio of the expression levels of the pro-apoptotic protein Bax to the anti-apoptotic protein BCL-2.
[0008] In the present invention, Bax / BCL-2 reflects the ability of cells to resist apoptosis.
[0009] The present invention also provides an application of Yangxin Dawa Yimixike honey paste in preparing the following ① or ② products: ① left ventricular ejection fraction increasing agent, ② left ventricular shortening fraction increasing agent.
[0010] In the present invention, the aforementioned Yangxin Dawa Yimixik Honey Paste is preferably sourced from Xinjiang Uygur Pharmaceutical Co., Ltd., with the national medicine standard Z65020175.
[0011] In the present invention, the dosage of the aforementioned Yangxin Dawa Yimixike honey paste can be 0.27-1.08 g / kg, for example 0.27 g / kg, 0.54 g / kg or 1.08 g / kg.
[0012] In the present invention, the product may be an oral pharmaceutical preparation.
[0013] The oral pharmaceutical preparation may be a suspension. The solvent of the suspension may be a 0.5% sodium carboxymethylcellulose aqueous solution, where the percentage refers to the mass percentage of the sodium carboxymethylcellulose in water.
[0014] The oral pharmaceutical preparation may also be any one of ointment, tablet, capsule, granule and powder.
[0015] The positive and progressive effects of the present invention are:
[0016] The present invention uses Yangxin Dawa Yimixike Honey Paste to prepare rehabilitation treatment products after myocardial infarction. The results show that the product has a significant protective effect on the rat heart, can significantly improve the heart function after myocardial infarction, prevent heart failure, reduce inflammatory infiltration, reduce the expression of apoptosis genes and proteins, and effectively inhibit the occurrence of cardiac fibrosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 is the left ventricular ejection fraction (LVEF) of the rats in Example 1 of the present invention.
[0018] Figure 2 It is the left ventricular fractional shortening (LVFS) of the rats in Example 1 of the present invention.
[0019] Figure 3 This is the effect of Yangxin Dawa Yimixike Honey Paste on serum inflammatory factor IL-1β and cardiac function marker NT-proBNP in Example 1 of the present invention.
[0020] Figure 4 This is Example 1 of the present invention, which shows the effect of Yangxin Dawa Yimixike Honey Paste on the morphological changes of myocardial cells in rats with myocardial infarction.
[0021] Figure 5 This is Example 1 of the present invention, which shows the effect of Yangxin Dawa Yimixike Honey Paste on myocardial cell apoptosis in rats with myocardial infarction.
[0022] Figure 6 This is Example 1 of the present invention, which shows the effect of Yangxin Dawa Yimixike Honey Paste on the mitochondrial structure and function of myocardial cells in rats with myocardial infarction.
[0023] Figure 7 This is the effect of Yangxin Dawa Yimixike Honey Paste on the degree of myocardial fibrosis in rats with myocardial infarction in Example 1 of the present invention.
[0024] Figure 8 This is Example 1 of the present invention, which shows the effect of Yangxin Dawa Yimixike Honey Paste on inflammation and apoptosis-related proteins in rats with myocardial infarction. DETAILED DESCRIPTION
[0025] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0026] Example 1
[0027] In this experiment, 90 SPF male Wistar rats weighing (200±15) g were purchased from Beijing Tonglihua Experimental Animal Technology Co., Ltd. with a certificate number of SCXK (Beijing) 2021-0006. They were kept in the animal room of Guang'anmen Hospital of China Academy of Chinese Medical Sciences at a constant room temperature of (25±1)°C, fed with standard diet and drinking water, and kept in a 12-h light and 12-h dark cycle in the room. The experimental protocol involving mice in the experiment was approved by the Animal Ethics Committee of Guang'anmen Hospital of China Academy of Chinese Medical Sciences (approval number
[0028] IACUC-GAMH-1023-050).
[0029] According to the literature [Guo Q, Wu D, Jia D, et al. Bioinformatics prediction and experimental verification of a novel microRNA for myocardial fibrosis after myocardial infarction in rats [J]. Peer J, 2023, 11: e14851.], a rat model of myocardial infarction by ligation of the left anterior descending coronary artery was established. After weighing, the rats were anesthetized with 10% chloral hydrate intraperitoneally and fixed on the operating table in a supine position. After tracheal intubation, the ventilator was turned on for assisted breathing. The left chest and neck of the rats were shaved and skinned, and disinfected with iodine. Ophthalmic grade scissors were used to penetrate from the strongest part of the apex pulsation, bluntly separated, and the heart was exposed. The anterior descending coronary artery was ligated at the distal end of the left atrial appendage. The apex changed from red to white, and the heart pulsation weakened, indicating that the model was successfully established. Clean the residual blood, squeeze the exhaust, and close the chest and suture. After surgery, the rats were placed on a heating pad until they woke up, and sodium penicillin was injected intramuscularly to prevent infection.
[0030] The surviving rats after surgery were randomly divided into sham operation group, model group, fosinopril group, Yangxin low-dose group (0.27g / kg), Yangxin medium-dose group (0.54g / kg) and Yangxin high-dose group (1.08g / kg). Gavage was started 2 hours after recovery from surgery, once a day for 4 consecutive weeks, during which time they ate and drank normally. The therapeutic drugs were all converted according to body surface area. The dose of fosinopril group was the equivalent daily dose of a 70kg adult, that is, 0.36g / kg. The therapeutic drugs were all suspensions prepared with 0.5% sodium carboxymethylcellulose aqueous solution. The sham operation group and the model group were treated with an equal amount of 0.5% sodium carboxymethylcellulose aqueous solution by gavage, 10mL / kg.
[0031] The Yangxin Dawa Yimixike honey paste in the above embodiment is derived from Xinjiang Uygur Pharmaceutical Co., Ltd., with the national medicine standard Z65020175.
[0032] Effect embodiment:
[0033] After 4 weeks of treatment, the results are shown in Table 1. Figure 1 and Figure 2 The left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) in the model group were significantly reduced, while the LVEF and LVFS in the different doses of Yangxin Mi Gao groups were significantly increased, and the cardiac function was significantly improved.
[0034] In the figure, ⅰ indicates a comparison with the sham operation group, P < 0.05, ⅱ indicates a comparison with the sham operation group, P < 0.01, ⅲ indicates a comparison with the model group, P < 0.05, and ⅳ indicates a comparison with the model group, P < 0.01; Figure 8 *, **, ***, and ### represent significance, ***P < 0.001, ### P<0.001, *P<0.05, **P<0.01.
[0035] Table 1
[0036]
[0037] Serum ELISA results showed that Figure 3 As shown in Table 2, compared with the sham operation group, the expressions of inflammatory factor IL-1β and cardiac function marker NT-proBNP in the model group were significantly increased, while different doses of Yangxin Mi Gao could reduce the expressions of inflammatory factors and NT-proBNP, thereby improving cardiac function and alleviating inflammatory response.
[0038] Table 2
[0039]
[0040] HE staining results showed that Figure 4 As shown, the myocardial cells in the model group were disorderly arranged, some cell nuclei were condensed, fragmented or even necrotic, muscle fibers were broken, and inflammatory infiltration was obvious. The overall morphology of myocardial cells in the low-dose Yangxin group was relatively clear, some muscle fibers were broken, a small amount of cell necrosis was visible, and the inflammatory infiltration was significantly improved. The effects of the medium and high-dose Yangxin groups were better than those of the low-dose group, indicating that Yangxin Dawa Yimixike Honey Paste can improve myocardial inflammatory infiltration and necrosis in rats with myocardial infarction.
[0041] TUNEL staining results showed that Figure 5 As shown, the myocardial cells of rats in the model group underwent apoptosis due to ischemia, and the number of TUNE-positive cells increased significantly. The degree of apoptosis in each dose group of Yangxin was significantly reduced, and the medium dose had the best effect, indicating that Yangxin Dawa Yimixike Honey Paste can inhibit myocardial cell apoptosis caused by myocardial infarction.
[0042] Mitochondrial ultramicroscopy results showed that Figure 6The mitochondria in the model group were disordered, swollen with vacuolar changes, loose in structure, and the double membrane structure was severely damaged, while the mitochondrial structure in the medium-dose group of Yangxin Honey Paste was significantly improved, and the double membrane was relatively intact, indicating that Yangxin Dawa Yimixike Honey Paste can significantly improve the myocardial mitochondrial structure and function caused by myocardial infarction.
[0043] Masson staining results showed that Figure 7 As shown, the myocardial fibers in the model group were severely broken, arranged extremely irregularly, and the collagen fibers significantly proliferated, while the myocardial tissues in all dose groups of Yangxin showed significant improvement, the myocardium ran more regularly, and the collagen fibers were significantly reduced, indicating that Yangxin Dawa Yimisike Honey Paste has a significant inhibitory effect on myocardial fibrosis.
[0044] Western blotting experiments showed that Figure 8 As shown in Table 3, compared with the sham operation group, the expression of mitochondrial membrane channel protein (VDAC1), NOD-like receptor pyrin domain-related protein 3 (NLRP3), and Bax / BCL-2 in the model group was significantly upregulated, and the expression of each protein in the different doses of Yangxin Mi Gao groups was significantly downregulated. Yangxin Mi Gao can improve the cardiac function of rats with myocardial infarction by downregulating the expression of VDAC1, and inhibit myocardial inflammatory response and apoptosis by downregulating the expression of NLRP3 and Bax / BCL-2, thereby further delaying and inhibiting myocardial fibrosis.
[0045] Table 3
[0046]
[0047] In summary, Yangxin Dawa Yimixike Honey Paste can improve left ventricular ejection fraction (LVEF) and left ventricular shortening fraction (LVFS), inhibit the expression of inflammatory factor IL-1β, cardiac function marker NT-proBNP, mitochondrial membrane channel protein (VDAC1), NOD-like receptor pyrin domain-related protein 3 (NLRP3), and Bax / BCL-2, effectively improve cardiac function after myocardial infarction, reduce myocardial inflammatory infiltration and necrosis, improve mitochondrial function, and inhibit the development of cardiac fibrosis. In some indicators (such as inhibition of mitochondrial membrane channel protein (VDAC1) expression and NT-proBNP expression), the effect is better than that of positive drugs (fosinopril group).
Claims
1. An application of Yangxin Dawa Yimixike honey paste in the preparation of myocardial infarction rehabilitation products, wherein the myocardial infarction is type 1 myocardial infarction.
2. Use of a Yangxin Dawa Yimixi honey paste in the preparation of the following ① or ② products: ① IL-1β expression inhibitor, ② NT-proBNP expression inhibitor.
3. A use of a Yangxin Dawa Yimixi honey paste in the preparation of any of the following products ① to ③: ① VDAC1 expression inhibitor, ② 3NLRP3 expression inhibitor, ③ Bax / BCL-2 inhibitor, Bax / BCL-2 refers to the ratio of the expression levels of the pro-apoptotic protein Bax to the anti-apoptotic protein BCL-2.
4. Use of a Yangxin Dawa Yimixike honey paste in the preparation of the following ① or ② products: ① left ventricular ejection fraction increaser, ② left ventricular shortening fraction increaser.
5. The use according to any one of claims 1 to 4, It is characterized in that The Yangxin Dawa Yimixik Honey Paste is sourced from Xinjiang Uyghur Pharmaceutical Co., Ltd., with the national medicine approval number Z65020175.
6. The use according to any one of claims 1 to 4, It is characterized in that The dosage of the Yangxin Dawa Yimixike honey paste is 0.27-1.08 g / kg.
7. The use according to claim 6, It is characterized in that The dosage of the Yangxin Dawa Yimixike honey paste is 0.27g / kg, 0.54g / kg or 1.08g / kg.
8. The use according to any one of claims 1 to 4, It is characterized in that The product is an oral pharmaceutical preparation.
9. The use according to claim 8, It is characterized in that The oral pharmaceutical preparation is any one of ointment, tablet, capsule, granule and powder.
10. The use according to claim 8, It is characterized in that The oral pharmaceutical preparation is a suspension, and the solvent of the suspension is a 0.5% sodium carboxymethylcellulose aqueous solution, where the percentage refers to the mass percentage of the sodium carboxymethylcellulose in water.
